Insider selling
Traded Dec 20, 2024 · filed 6 days laterNot reported under a pre-arranged trading plan
Biocardia's Senior Vice President, Devices sold $6.5K of Biocardia shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Dec 23, 2024 · Filed Dec 26, 2024
The CEO of Biocardia paid $2.1K out of pocket for Biocardia shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$2,060
Shares × reported transaction price
<$25K
+0.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2023 ($863K)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2025-11-03. The proxy does not tag the CEO's name, so the match rests on the Form 4 title only. A size comparison, not a judgement
40 days after results of Nov 13, 2024, 93 days before results of Mar 26, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −6.1% | −0.5% | −5.6% |
| 30 days | −7.7% | +0.7% | −8.4% |
| 90 days | +8.9% | −4.7% | +13.6% |
| 180 days | −8.5% | +2.0% | −10.6% |
| 365 days | −50.0% | +15.6% | −65.6% |
Past results only. Not a forecast.
Insider selling
Traded Dec 20, 2024 · filed 6 days laterNot reported under a pre-arranged trading plan
Biocardia's Senior Vice President, Devices sold $6.5K of Biocardia shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Dec 5, 2024 · filed 4 days later
The CEO of Biocardia paid $555 out of pocket for Biocardia shares.
Insider buying
Traded Nov 15, 2024 · filed 4 days later
The CEO of Biocardia paid $2.5K out of pocket for Biocardia shares. It was the first purchase in over a year.
Peter Altman, President and CEO's past purchases, 90 days after disclosure: 38 buys, median −9.0 pts vs S&P 500, beat it 13 of 38 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.